Stockscreener 앱 받기
63.65
1.86%
1.1237
전일 마감가:
$62.53
열려 있는:
$62.565
하루 거래량:
920.69K
Relative Volume:
0.15
시가총액:
$24.82B
수익:
$4.30B
순이익/손실:
$571.50M
주가수익비율:
44.56
EPS:
1.4285
순현금흐름:
$570.80M
1주 성능:
+5.75%
1개월 성능:
-7.99%
6개월 성능:
-26.77%
1년 성능:
-18.44%
1일 변동 폭
$62.23
$63.95
1주일 범위
$60.07
$64.00
52주 변동 폭
$54.11
$93.25
덱스컴 Stock (DXCM) Company Profile
명칭
Dexcom Inc
전화
(858) 200-0200
주소
6340 SEQUENCE DRIVE, SAN DIEGO, CA
DXCM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
63.65 | 24.39B | 4.30B | 571.50M | 570.80M | 1.4285 |
|
ABT
Abbott Laboratories
|
129.15 | 223.51B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
101.57 | 149.67B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
371.70 | 142.37B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
104.91 | 134.64B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
86.85 | 50.34B | 5.88B | 1.34B | 799.60M | 2.3489 |
덱스컴 Stock (DXCM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-21 | 재개 | Stifel | Buy |
| 2025-09-08 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2025-08-21 | 개시 | Argus | Buy |
| 2025-06-16 | 개시 | Truist | Buy |
| 2025-05-30 | 개시 | Goldman | Buy |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-02-03 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-07-26 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | 개시 | Redburn Atlantic | Neutral |
| 2024-03-12 | 개시 | RBC Capital Mkts | Outperform |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-04-17 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | 개시 | UBS | Buy |
| 2023-01-26 | 개시 | Wolfe Research | Outperform |
| 2022-10-18 | 개시 | Barclays | Equal Weight |
| 2022-10-12 | 개시 | Jefferies | Buy |
| 2022-07-15 | 개시 | Bernstein | Outperform |
| 2022-03-02 | 재개 | BofA Securities | Buy |
| 2022-02-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2022-01-19 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-10-18 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-07-21 | 재개 | Cowen | Outperform |
| 2021-05-28 | 업그레이드 | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | 개시 | Barclays | Overweight |
| 2021-04-15 | 개시 | Atlantic Equities | Overweight |
| 2021-01-06 | 업그레이드 | UBS | Neutral → Buy |
| 2020-10-02 | 다운그레이드 | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | 재확인 | Piper Sandler | Overweight |
| 2020-05-14 | 개시 | Wells Fargo | Equal Weight |
| 2020-03-05 | 개시 | Citigroup | Buy |
| 2019-11-07 | 재확인 | Canaccord Genuity | Buy |
| 2019-11-07 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2019-10-23 | 개시 | Stifel | Buy |
| 2018-11-28 | 개시 | UBS | Neutral |
| 2018-10-19 | 업그레이드 | Goldman | Sell → Neutral |
| 2018-09-12 | 업그레이드 | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | 재확인 | Canaccord Genuity | Buy |
| 2018-07-02 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2018-05-11 | 개시 | BofA/Merrill | Buy |
| 2018-05-03 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-04 | 개시 | Goldman | Sell |
| 2018-04-04 | 개시 | Guggenheim | Neutral |
| 2018-03-23 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | 다운그레이드 | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | 재확인 | Wedbush | Outperform |
모두보기
덱스컴 주식(DXCM)의 최신 뉴스
Synopsys, Inc. Sued for Securities Law Violations - GlobeNewswire Inc.
DXCM 截止日期提醒：全球投資者法律顧問 ROSEN 鼓勵 DexCom, Inc. 投資者在對 DXCM 提出證券集體訴訟的重要截止日期前聘請律師 - GlobeNewswire Inc.
DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit with the Schall Law Firm - GlobeNewswire
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Here’s Why Dexcom (DXCM) Traded Down in Q3 - Insider Monkey
DXCM DEADLINE ALERT: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. Investors to ... - Bakersfield.com
Artificial Intelligence in Remote Patient Monitoring Market Projected to Reach $14.51 Billion by 2032, Growing at a CAGR of 27.52% - GlobeNewswire Inc.
Evercore ISI Begins Coverage on DexCom (NASDAQ:DXCM) - Defense World
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DXCM Deadline: DXCM Investors Have Opportunity to Lead DexCom, Inc. Securities Fraud Lawsuit - MarketScreener
DXCM INVESTORS: Contact Kirby McInerney LLP About Securities Class Action Lawsuit On Behalf of DexCom, Inc. - Business Wire
DexCom (DXCM): Positive Outlook Amid Medicare Payment Report - GuruFocus
Labaton Keller Sucharow LLP Announces Expanded Securities Class Action Lawsuit Filed Against DexCom, Inc. and Certain Executives - Business Wire
DXCM Class Action Alert: Kessler Topaz Meltzer & Check, LLP Reminds DexCom, Inc. (DXCM) Shareholders of Securities Fraud Class Action Lawsuit Deadline - NewMediaWire
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing Deadline in Securities Class ActionContact Lieff Cabraser - ACCESS Newswire
GlucoGuard a Division of American Diversified Holdings (ADHC) Successfully Submits Level 2 App Integration Through Dexcom's Developer Partner Program - TradingView
Morgan Stanley, Truist Cautious on DexCom (DXCM) Cites Weaker Gross Margins, Modest Q3 Beat - Finviz
Shareholders that lost money on DexCom, Inc.(DXCM) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - Morningstar
Carillon Eagle Mid Cap Growth Fund’s Views on Dexcom (DXCM) - Insider Monkey
Evercore Initiates Coverage on DexCom With In Line Rating, $68 Price Target - MarketScreener
Elanco, AMN Healthcare Services, Brookdale, DexCom, and Addus HomeCare Shares Skyrocket, What You Need To Know - TradingView
Investors in DexCom, Inc. Should Contact The Gross Law Firm Before December 26, 2025 to Discuss Your RightsDXCM - Your Wyoming Link
DexCom, Inc. (DXCM) Investors: December 26, 2025 Filing - GlobeNewswire
DexCom, Inc. Class Action: The Gross Law Firm Reminds - GlobeNewswire
Lowey Dannenberg Notifies DexCom, Inc. (“DexCom” or the - GlobeNewswire
Ademi & Fruchter LLP Investigates Claims of Securities Fraud against DexCom, Inc. - PR Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
DXCM Stock Falls Despite FDA Clearance for Dexcom Smart Basal - MSN
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages DexCom, Inc. - GlobeNewswire
Kessler Topaz Meltzer & Check, LLP Notifies DexCom, Inc. Investors of Upcoming Deadline in Securities Fraud Class Action Lawsuit - The Globe and Mail
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of DexCom, Inc. to Contact the Firm Today! - ACCESS Newswire
DXCM Announcement: Kessler Topaz Meltzer & Check, LLP Encourages DexCom, Inc. (DXCM) Investors to Contact the Firm About Securities Fraud Class Action Lawsuit - The Malaysian Reserve
Bank Julius Baer & Co. Ltd Zurich Sells 8,697 Shares of DexCom, Inc. $DXCM - Defense World
AbbVie, Biogen, BioMarin Pharmaceutical, DexCom, and Abbott Laboratories Stocks Trade Up, What You Need To Know - Yahoo Finance
DXCM INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
DXCM LAWSUIT ALERT: Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - NewMediaWire
DexCom, Inc. Sued for Securities Law ViolationsContact the DJS Law Group to Discuss Your RightsDXCM - MarketScreener
DexCom Inc. Stock Underperforms Thursday When Compared To Competitors - 富途牛牛
DXCM SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that DexCom, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
ROSEN, SKILLED INVESTOR COUNSEL, Encourages DexCom, Inc. - GlobeNewswire
DCXM DEADLINE ALERT: DexCom, Inc. Investors Urged to Contact Kirby McInerney LLP About Class Action Lawsuit - GlobeNewswire
Dexcom (DXCM) Valuation: Assessing Upside After FDA Clearance of Smart Basal Diabetes Device - Yahoo Finance
Levi & Korsinsky Notifies Shareholders of DexCom, Inc. (DXCM) of a Class Action Lawsuit and an Upcoming Deadline - GlobeNewswire
Dexcom Smart Basal Receives FDA Clearance for Personalized Basal Insulin Dosing - Pharmacy Times
Levi & Korsinsky Notifies DexCom, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineDXCM - NewMediaWire
DXCM Deadline Alert: Kessler Topaz Meltzer & Check, LLP - GlobeNewswire
Dexcom to Release G7 15 Day CGM Next Month - Medical Product Outsourcing
Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch on Dec. 1 in the United States - GuruFocus
Dexcom G7 15 day continuous glucose monitoring system to launch on Dec. 1 in the United States - MarketScreener
Dexcom G7 15 Day Continuous Glucose Monitoring System To Launch On Dec. 1 In The United States - TradingView
The Gross Law Firm Reminds DexCom Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of December 26, 2025DXCM - PR Newswire
덱스컴 (DXCM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.09%
0.29%
자본화:
|
볼륨(24시간):